|Bid||0.0000 x 1100|
|Ask||0.0000 x 800|
|Day's Range||1.7000 - 2.0900|
|52 Week Range||0.6500 - 3.2500|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.00|
With a $30 million investment from a single Cary-based firm, one Durham pharmaceutical company is "set loose" to run multiple trials.
Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that recent data from the Company’s Phase 1b trial with SB414 cream for the treatment of atopic dermatitis and Phase 2 trial with SB206 gel for the treatment of molluscum contagiosum will be presented at the 77th Annual Meeting of the Annual Meeting of the Society for Investigative Dermatology. Clinical and biomarker results from the Company’s Phase 1b atopic dermatitis trial will be presented during an oral presentation on May 9, 2019 and during a poster session on May 11, 2019.
In an continued effort to fund the company without hurting its already-down stock value, Novan has announced another $12 million deal to forward its lead drug trials.
Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that the Company has secured $12 million in non-dilutive capital from Ligand Pharmaceuticals Incorporated (“Ligand”) (LGND). This transaction further enables the accelerated advancement of the molluscum Phase 3 program within the overall Novan mid-to-late stage clinical development portfolio. Under the terms of this development funding and royalty agreement, Ligand will provide funding of $12 million in exchange for a tiered royalty of 7 to 10% which will be based on future North American sales of SB206 for the molluscum indication.
Novan, Inc. ("the Company" or "Novan") (NOVN) today confirmed that the Company will host a conference call tomorrow, Thursday, May 2, 2019 at 8:15 am Eastern Time to provide an update on the Company’s recent financing, clinical development plan and business model.
With just a over a month of its cash runway left, Novan has come up big with $35 million – but that capital comes with strings attached.
Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that the Company has secured up to $35 million in non-dilutive capital to advance Novan’s late-stage dermatology assets. Of this, $25 million is available immediately and $10 million is contingent upon achieving positive Phase 3 clinical trial results for molluscum contagiosum. This funding will allow Novan to immediately initiate the pivotal Phase 3 molluscum program.
One of the Triangle’s public companies continues to face hardships, as Novan’s stock dives away from the value it needs to stay on the stock exchange.
NOVAN INC (NOVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that the Company has named Dr. Elizabeth Messersmith, the Company’s Senior Vice President and Chief Development Officer, the chairperson of the Joint Committee responsible for overseeing the Company’s alliance with Sato Pharmaceutical Co., Ltd. (“Sato”).
Novan, Inc. ("the Company" or "Novan") (NOVN) today announced a number of recent business advancements. Novan concluded an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding SB206 for the treatment of molluscum.
New CLARITY data show over two-thirds of Cosentyx (secukinumab) treated patients with moderate to severe psoriasis reported no impact of skin disease on their quality of life (QoL) up to Week 16 compared ...
Phase III study shows close to 9/10 patients who received Cosentyx® 300mg achieved clear or almost clear skin during the first 16 weeks of treatment (87%), with rapid onset of relief seen as early as week ...
Shareholders approve 22 nd consecutive dividend increase to CHF 2.85 (+2%) per share for 2018; representing a 3.1% yield and approximately 57% payout of free cash flow Overwhelming majority of shareholders ...
Basel, February 25, 2019 - Novartis today published certain key financial information for the Alcon eye care business covering the full year 2018 ahead of a vote on the proposed 100% spin-off of Alcon ...
Novartis announced today that it is exercising its option to license the rights to develop and commercialize TQJ230, an investigational agent previously known as AKCEA-APO(a)-LRx, from Akcea Therapeutics, ...
Novartis announced today that the US Food and Drug Administration (FDA) has approved Egaten® (triclabendazole) for the treatment of fascioliasis in patients six years of age and older. This makes Egaten the only FDA-approved drug for people with this disease and is expected to facilitate broader access to this important drug not only in the US, but also in affected countries worldwide.
Novan, Inc. ("the Company" or "Novan") (NOVN) today provided an update on several aspects of its business. Novan announces that it has been granted an end-of-Phase 2 meeting with the FDA in early March 2019 for the SB206 molluscum program.
After years and ups and downs while the company has been trying to push out their nitric oxide candidates, Novan now faces a delisting threat due to steadily decreasing stock value.
Jim Cramer and Novartis CEO Vas Narasimhan discuss how the drugmaker is refocusing its business to leverage new-age treatments and potential cures.